Skip to main content
. 2012 Jul 3;23(1):13–18. doi: 10.1111/j.1750-3639.2012.00609.x

Figure 2.

figure

Cumulative survival of patients with diffuse astrocytoma is significantly shorter for tumors with MET gain than for tumors without MET gain (median overall survival, 43.0 months vs. 70.7 months; P = 0.004). There was no significant difference in patient survival for glioblastomas with or without MET gain.